Skip to main content

Table 3 Molecular and microbiological characteristics of carbapenemase-producing Enterobacterales isolates

From: Institutional outbreak involving multiple clades of IMP-producing Enterobacter cloacae complex sequence type 78 at a cancer center in Tokyo, Japan

Patient No. Isolate name Date of isolation Bacterial species of CPE (ANI)a Sequence type Cladeb Antimicrobial susceptibilityc MIC (mg/mL)d Antimicrobial resistance genes Plasmid repliconse
TZP FEP ATM LVX SXT GEN AMK IPM MEM   
1 TUM 14647 Jul. 2014 E. hormaechei 78 A R R R S S S S 4 4 blaIMP-1, blaACT-5, aac(6′)-IIc, qnrB6, fosA, sul1, tet(B) IncHI2A/IncHI2
2 TUM 14648 Jul. 2014 2 4
3 TUM 14652 Aug. 2014 4 4
4 TUM 14654 Sep. 2014 4 2
5 TUM 14658 Sep. 2014 4 2
6 TUM 14792 Sep. 2014 4 2
7 TUM 14797 Nov. 2014 4 4
8 TUM 17939 Feb. 2015 4 2 IncHI2A/IncHI2
9 TUM 17940 Apr. 2015 I R I I R S S > 4 > 4
13 TUM 17944 Jul. 2015 R R R S S S S 4 2
11 TUM 17942 Apr. 2015 B R SDD S R R S S 4 ≤1 blaIMP-11, blaTEM-1B, blaACT-5, aac(6′)-Ia, qnrS1, fosA, sul1 IncFIB (pHCM2)
IncL/M (pMU407)
12 TUM 17943 May 2015 C R R R S S S S > 4 4 blaIMP-1, blaACT-5, aac(6′)-IIc, aph(3″)-1b, aph(6)-1d, qnrB6, fosA, sul1, sul2, tet(B) IncHI2A/IncHI2
14 TUM 17945 Jul. 2015 4 4
15 TUM 17946 Aug. 2015 4 4
10 TUM 17941 Apr. 2015 E. asburiae 24 NA R R S S S S S 4 4 blaIMP-1, blaACT-1, aac(6′)-IIc, fosA, sul1 IncFII (pECLA)/
IncFIB (pECLA)
16 TUM 17947 Sep. 2015 E. xiangfangensis 1331 NA R R R S S S S 4 4 blaIMP-1, blaACT-16, aac(6′)-IIc, strA, aph(6)-1d, qnrS1, fosA, sul1, tet(B) IncHI2A/IncHI2
IncFIB (pECLA)
17 TUM 17948 Oct. 2015 E. hormaechei subsp. steigerwaltii 113 NA S R S S S S S 4 2 blaIMP-1, blaACT-15, aadA1, aac(6′)-IIc, qnrB6, fosA, sul1 IncHI2A/IncHI2
IncFII (pECLA)/
IncFIB (pECLA)
18 TUM 17949 Apr. 2017 E. hormaechei subsp. steigerwaltii 133 NA R R S I S S S 2 ≤1 blaIMP-1, blaACT-7, aac(6′)-IIc, qnrB6, fosA, sul1, tet(B) IncHI2A/IncHI2
  1. a Bacterial species and subspecies confirmed by the comparison of average nucleotide identity of study isolates with those of type strains were presented
  2. b Clades of ST78 isolates determined by core-genome single nucleotide polymorphism-based analysis were presented
  3. c Results of antimicrobial susceptibility testing performed with BD Phoenix NMIC/ID-208 panel and interpreted according to CLSI M100-S27 guidelines were shown
  4. d Minimum inhibitory concentrations determined with BD Phoenix NMIC/ID-208 panel were presented
  5. e Plasmid replicon was underlined if a transconjugant of the isolates was positive for the replicon by PCR-based replicon typing
  6. ANI average nucleotide identity, NA Not applicable, ST sequence type, TZP piperacillin-tazobactam, CTX cefotaxime, CAZ ceftazidime, FEP cefepime, ATM aztreonam, IPM imipenem, MEM meropenem, LVX levofloxacin, SXT trimethoprim-sulfamethoxazole, GEN gentamicin, AMK amikacin, S Susceptible, SDD Susceptible-Dose Dependent, I Intermediate, R Resistant